D-DIBOA (4-hydroxy-(2H)-1,4-benzoxazin-3-(4H)-one) is an allelopathic-derived compound with interesting herbicidal, fungicidal, and insecticide properties whose production has been successfully achieved by biocatalysis using a genetically engineered strain. However, improvement and scaling-up of this process are hampered by the current methodology for D-DIBOA quantification, which is based on high-performance liquid chromatographic (HPLC), a time-consuming technique that requires expensive equipment and the use of environmentally unsafe solvents. In this work, we established and validated a rapid, simple, and sensitive spectrophotometric method for the quantification of the D-DIBOA produced by whole-cell biocatalysis, with limits of detection and quantification of 0.
View Article and Find Full Text PDFObjective: To assess 6-year-old cocaine- and noncocaine-exposed children's mental health outcomes controlling for potential confounders.
Methods: The sample consisted of 322 children [169 cocaine exposed (CE) and 153 noncocaine exposed (NCE)] enrolled in a longitudinal study since birth. At age 6, children were assessed for mental health symptoms using the Dominic Interactive (DI), a child self-report measure, and the Child Behavior Checklist (CBCL), a caregiver report of behavioral problems.
Purpose: Using a case-control design, patterns of drug use, psychological symptoms, and behavioral characteristics associated with 3,4-methylenedioxymethamphetamine (MDMA ) use were surveyed in a sample of older adolescents (median age 20).
Methods: One hundred (42 MDMA users; 58 non-MDMA users) older adolescents were recruited using the "snowball" technique and interviewed regarding their use of MDMA and other drugs. The Brief Symptom Inventory (BSI), the Problem Oriented Screening Instrument for Teenagers (POSIT), the HIV/sexually transmitted diseases (STD) risk scale, and the Childhood Trauma Questionnaire (CTQ) were also administered.